The company did not fire Menon. He resigned, likely into retirement, with no conflict with the company. Hopefully his years of work on Kevetrin and Brilacidin will bear fruit for him and all shareholders. If the resignation was an act of accountability for the Prurisol failure then that is fine as well.
I'm not sure why you're so focused on the lease either. $19,000 a month is a drop in the bucket. That's not going to make or break our company. We are continuing preclinical/formulation work on multiple indications and need appropriate office space to do so.
2019 will be better. The company has little choice and much incentive to do a deal. A clear path forward with some cash in the bank will allow the market to give us forward-looking credit once more. You will see.
News 
Market Data 
Discover 
